North Carolina-based KBI Biopharma signed an agreement with Merck & Co. to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014.
Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers. The acquisition will enable KBI to offer expanded microbial development and manufacturing services up to 1500L scale.
KBI is a contract development & manufacturing organization serving biopharmaceutical clients in the accelerated development of innovative medicines for global patients.
Read the press release